Can-Fite BioPharma Ltd. CANF
AMEX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -9.55M | -9.69M | -9.83M | -9.31M | -8.80M |
| Total Depreciation and Amortization | 2.00K | 13.00K | 24.00K | 26.50K | 29.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 168.00K | 295.00K | 422.00K | 438.50K | 455.00K |
| Change in Net Operating Assets | -128.00K | 152.50K | 433.00K | 197.50K | -38.00K |
| Cash from Operations | -9.51M | -9.23M | -8.95M | -8.65M | -8.35M |
| Capital Expenditure | -2.00K | -2.00K | -2.00K | -2.00K | -2.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -4.00M | -2.00M | 0.00 | 0.00 | 0.00 |
| Cash from Investing | -4.00M | -2.00M | -2.00K | -2.00K | -2.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 10.04M | 9.84M | 9.64M | 10.12M | 10.60M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -256.00K | -512.00K |
| Cash from Financing | 10.04M | 9.84M | 9.64M | 9.86M | 10.08M |
| Foreign Exchange rate Adjustments | 1.00K | 5.50K | 10.00K | 8.00K | 6.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.47M | -1.38M | 703.00K | 1.22M | 1.74M |